Sun Pharmaceutical Industries Limited
All news and filings related to Sun Pharmaceutical Industries Limited.
View all news & filings- Medium impact
Sun Pharma to Host Investor Call on Organon & Co. Acquisition Today, April 27, 2026
Sun Pharmaceutical Industries Limited will hold an investor call on 27 April 2026 at 8:00 am IST to discuss the acquisition of Organon & Co. Senior management will present updates on the announced asset. Participation is via Zoom.
Read the summary - High impact
Sun Pharma to Acquire Organon for $11.75 Billion in Cash
Sun Pharma will acquire Organon & Co. for US$11.75 billion in an all-cash deal. Organon, with over 70 products in Women's Health and General Medicines, reported US$6.2 billion in revenue for FY2025. The acquisition aims to enhance Sun Pharma's global scale and product portfolio, with completion expected in early 2027.
Read the summary - Low impact
Sun Pharma Incorporates New Subsidiary in USA
Sun Pharmaceutical Industries Limited announced the incorporation of its wholly-owned subsidiary, Sun Pharma America, Inc., in the USA on April 23, 2026. This is for internal group structuring, with an initial cash consideration.
Read the summary - Low impact
Sun Pharma Shareholders Approve Cost Auditor Remuneration, MOA Alteration, and Re-appoint Dr. Pawan Goenka as Director
Sun Pharma's postal ballot concluded on April 17, 2026. Shareholders approved the cost auditor's remuneration for FY26, an alteration to the Memorandum of Association, and re-appointed Dr. Pawan Goenka as Independent Director for a five-year term starting May 21, 2026.
Read the summary - Low impact
Sun Pharma Denies Speculative News on $12 Billion Organon Deal
Sun Pharma denies speculative news regarding a potential $12 billion deal with Organon, as reported on April 10, 2026. The company stated there is no material event requiring disclosure under SEBI regulations. Sun Pharma commits to timely disclosure of any material information.
Read the summary - Low impact
Sun Pharma Publishes Newspaper Ads on Postal Ballot/E-Voting Information
Sun Pharmaceutical Industries Limited published newspaper advertisements on April 8, 2026, regarding postal ballot and e-voting information. The ads appeared in Financial Express (English and Gujarati editions). Copies are available on the company website.
Read the summary - Low impact
Sun Pharma Seeks Shareholder Approval for Ms. Satyavati Berera's Independent Director Appointment
Sun Pharma is seeking shareholder approval to appoint Ms. Satyavati Berera as an Independent Director for a five-year term. The e-voting period is from April 9 to May 8, 2026. Ms. Berera brings extensive experience in finance and governance from her tenure at PwC India.
Read the summary - Low impact
Sun Pharma Submits Certificate Under SEBI Depositories Regulations
Sun Pharma submitted a confirmation certificate for Q4 FY26, received from its Registrar & Share Transfer Agent, MUFG Intime India Pvt. Ltd. This certificate confirms compliance with SEBI (Depositories and Participants) Regulations, 2018, regarding the processing of dematerialised securities for the quarter ended March 31, 2026.
Read the summary - Medium impact
Sun Pharma Appoints Ms. Satyavati Berera as Independent Director
Sun Pharma appointed Ms. Satyavati Berera as an Independent Director for a five-year term, subject to shareholder approval. Ms. Berera previously served as COO of PwC India and brings extensive experience in finance, operations, and governance.
Read the summary - Medium impact
Sun Pharma's Fibromun and Nidlegy Trials Show Mixed Results, New Registrational Studies Planned
Sun Pharma's partner Philogen reported mixed results for Fibromun in soft tissue sarcoma and glioblastoma. New registrational studies (FIBROSARC-2, BCC, cSCC) are planned for Q2 2026 and mid-2026. Nidlegy™ shows promise in skin cancers, with a US melanoma trial ongoing and new submissions planned in Europe.
Read the summary - Low impact
Sun Pharma Presents 14 Abstracts on Dermatology Research at 2026 AAD Annual Meeting
Sun Pharma presented 14 abstracts at the 2026 AAD Annual Meeting from March 27-31. The presentations covered research advances in alopecia areata, psoriasis, and acne, featuring data on ILUMYA®, LEQSELVI™, and WINLEVI®. The company highlighted its commitment to developing effective treatments for chronic dermatological conditions.
Read the summary - Low impact
Sun Pharma to Close Trading Window from April 1 for FY26 Audited Results
Sun Pharma will close its trading window from April 1, 2026. The closure will last until 48 hours after the announcement of audited financial results for the fiscal year ending March 31, 2026. The board meeting date for approving results will be announced later.
Read the summary - Medium impact
Sun Pharma Launches Semaglutide Injections Noveltreat & Sematrinity in India
Sun Pharma launched semaglutide injections, Noveltreat for weight management and Sematrinity for type 2 diabetes, in India. Priced affordably, weekly therapy costs range from ₹750 to ₹2,000. The company aims to provide accessible, high-quality treatment options backed by a patient support program.
Read the summary - Low impact
Sun Pharma Publishes Newspaper Advertisements Regarding Postal Ballot/E-Voting
Sun Pharma published newspaper advertisements on March 18, 2026, regarding a postal ballot and e-voting. The e-voting period is from March 15, 2026, to April 17, 2026. Shareholders are urged to update their contact details for participation.
Read the summary - Medium impact
Sun Pharma Seeks Shareholder Approval Via Postal Ballot for Cost Auditor, MOA Alteration & Director Re-appointment
Sun Pharma is seeking shareholder approval through postal ballot for three resolutions: ratifying Cost Auditor remuneration of ₹31.26 lakh for FY26, amending MOA for power generation activities, and re-appointing Dr. Pawan Goenka as Independent Director for a second 5-year term from May 21, 2026. E-voting is open from March 19 to April 17, 2026.
Read the summary - Low impact
Sun Pharma Launches Shareholder Satisfaction Survey on RTA Services
Sun Pharma has launched a Shareholder Satisfaction Survey on RTA services provided by MUFG Intime India Private Limited. The survey runs from March 17 to March 31, 2026, and seeks feedback from shareholders who used RTA services between April 1, 2025, and December 31, 2025.
Read the summary - Medium impact
Sun Pharma's ILUMYA sBLA for Psoriatic Arthritis Accepted by US FDA
Sun Pharma's supplemental Biologics License Application (sBLA) for ILUMYA® for active psoriatic arthritis has been accepted for review by the US FDA. The FDA decision is expected by October 29, 2026. This application is based on positive Phase 3 study results.
Read the summary - Low impact
Sun Pharma Presents Investor Presentation for February 2026
Sun Pharma released its February 2026 investor presentation, detailing its global operations, financial performance, and strategic initiatives. The company highlighted strong growth in sales and profitability, with a diversified revenue base across key markets. R&D investment remains a focus, alongside its extensive manufacturing capabilities and a history of strategic acquisitions.
Read the summary - Low impact
Sun Pharma Informs about SEBI's Special Window for Physical Share Transfers
Sun Pharma announces SEBI's special window for physical share transfers, open from Feb 5, 2026, to Feb 4, 2027. This facilitates transfers of shares sold/purchased before April 1, 2019. Transferred shares will be credited to demat accounts and locked in for one year.
Read the summary - High impact
Sun Pharma Q3 FY26 Net Profit Rises 16% to ₹3,369 Crore
Sun Pharma's Q3 FY26 net profit rose 16% to ₹3,369 crore on sales of ₹15,469 crore, up 15.1%. EBITDA increased 23.4% to ₹4,948 crore. The company declared an interim dividend of ₹11 per share. Key launches include Unloxcyt (US) and Ilumya (India), with Semaglutide planned for India.
Read the summary - Low impact
Sun Pharma to Participate in Multiple Analyst/Investor Meetings in Feb 2026
Sun Pharma will attend several analyst and institutional investor meetings in February 2026. These include the Nuvama India Conference, Systematix India Annual Conference, Axis Capital's India Conference, Kotak Securities' CHASING GROWTH 2026, and IIFL's Investors' Conference. No UPSI will be disclosed.
Read the summary - Low impact
Sun Pharma Releases Sustainability Report for FY24-25
Sun Pharma released its FY24-25 Sustainability Report. Key achievements include a 21% reduction in Scope 1 & 2 carbon emissions (vs. 2020 baseline), 41% renewable energy usage, and a 25% reduction in water consumption. The company invested ₹1,424 Million in CSR, impacting 4.47 million lives. It aims for 30% female workforce representation by 2040.
Read the summary - Low impact
Sun Pharma Files Unaudited Financial Results for Q3 FY26
Sun Pharmaceutical Industries Limited announced its Unaudited Financial Results for the quarter and nine months ended December 31, 2025. The results have been filed with the stock exchanges and are available on the company's website. Newspaper advertisements were published on February 1, 2026.
Read the summary - Low impact
Sun Pharma Q3 FY26 Earnings Call Audio Recording Available
Sun Pharmaceutical Industries Limited has released the audio recording of its Q3 FY26 earnings call held on January 31, 2026. The recording is accessible on the company's website via a direct link. This follows the initial earnings call intimation dated January 21, 2026.
Read the summary - Low impact
Sun Pharma Reappoints Dr. Pawan Goenka as Independent Director for 5 Years
Sun Pharma's Board approved Dr. Pawan Goenka's re-appointment as Independent Director for a second five-year term starting May 21, 2026. Ms. Rama Bijapurkar will retire as Independent Director on May 20, 2026.
Read the summary - High impact
Sun Pharma Declares ₹11 Interim Dividend; Q3FY26 Consolidated Sales Up 15.1% to ₹154,691 Crore
Sun Pharma declared an interim dividend of ₹11 per share. For Q3FY26, consolidated sales rose 15.1% YoY to ₹154,691 million. Net profit increased 16.0% YoY to ₹33,688 million. Nine-month sales grew 11.3% YoY to ₹436,604 million. India Formulation sales grew 16.2% to ₹49,986 million.
Read the summary - High impact
Sun Pharma Declares ₹11 Interim Dividend, Q3FY26 Net Profit Rises 16% to ₹33,688 Million
Sun Pharma reported Q3FY26 consolidated sales of ₹154,691 million (up 15.1% YoY) and a net profit of ₹33,688 million (up 16.0% YoY). The company declared an interim dividend of ₹11 per share. For nine months, sales were ₹436,604 million (up 11.3% YoY) and net profit was ₹87,654 million. India formulation sales grew 16.2% to ₹49,986 million.
Read the summary - Medium impact
Sun Pharma Gets DCGI Nod for Generic Semaglutide Injection for Weight Management
Sun Pharma received DCGI approval to manufacture and market a generic version of semaglutide injection in India for chronic weight management, to be sold under the brand name Noveltreat after patent expiry. The product, approved after Phase III trials in India, will come in five dose strengths, with a maintenance dose of 2.4 mg weekly. This follows Sun Pharma's December 2025 DCGI approval for semaglutide injection to treat type 2 diabetes.
Read the summary - Low impact
Sun Pharma to Announce Q3 FY26 Results on Jan 31, 2026; Earnings Call Scheduled
Sun Pharmaceutical Industries Limited will announce its third quarter results for the period ending December 31, 2025, on January 31, 2026. An earnings call is scheduled for the same day at 06:30 pm IST, where management will discuss performance.
Read the summary - Medium impact
Sun Pharma Board Meeting on Jan 31 to approve Q3 results and interim dividend
Sun Pharma's Board Meeting on January 31, 2026, will approve Q3 FY26 results and consider an interim dividend. The record date for the dividend is February 5, 2026. The trading window closes January 1 and reopens February 2.
Read the summary - Low impact
Sun Pharma Denies Speculative News on USD 10 Billion Organon Acquisition
Sun Pharma has denied speculative news regarding a potential USD 10 billion acquisition of Organon. The company clarified that the information is speculative and no material event requiring disclosure has occurred. Sun Pharma reiterated its commitment to governance and timely disclosures.
Read the summary - Medium impact
Sun Pharma's UNLOXCYT™ Approved for Advanced Cutaneous Squamous Cell Carcinoma in US
Sun Pharma's UNLOXCYT™ (cosibelimab-ipdl) is now available in the U.S. for advanced cutaneous squamous cell carcinoma (aCSCC). The drug offers durable efficacy with a 71% disease control rate and a proven tolerability profile. Sun Pharma is committed to ensuring patient access through the UNLOXCYT SUPPORT™ program.
Read the summary - Low impact
Sun Pharma Submits SEBI Confirmation Certificate for Q3 FY26
Sun Pharmaceutical Industries Limited submitted a SEBI confirmation certificate for the quarter ended December 31, 2025. The certificate, received from registrar MUFG Intime India Pvt. Ltd., confirms the processing and listing of dematerialized securities.
Read the summary - Low impact
Sun Pharma: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results
Sun Pharma's trading window will be closed from January 1, 2026, until 48 hours after the declaration of Q3 FY26 unaudited financial results. The board meeting date for approving these results will be announced later.
Read the summary - Medium impact
Sun Pharma Presents Investor Presentation for December 2025
Sun Pharma released its December 2025 investor presentation, showcasing diversified revenue and strong financial growth. FY25 sales reached ₹520.41 Bn with EBITDA of ₹152.72 Bn. Q2 FY26 saw Gross Sales rise 8.6% to ₹144.05 Bn. The company emphasizes its global presence, R&D investments, and strategic focus on innovative medicines and complex generics.
Read the summary - Low impact
Sun Pharma Publishes Newspaper Advt. on Special Window for Transfer Deeds
Sun Pharma is publishing newspaper advertisements and social media posts about a special window for re-lodging transfer deeds. This window, open from July 7, 2025, to January 6, 2026, is for deeds lodged before April 1, 2019, that were rejected.
Read the summary - Medium impact
Sun Pharma's Baska Facility Receives OAI Classification from US FDA
Sun Pharma's Baska facility received an Official Action Indicated (OAI) classification from the US FDA following an inspection from September 8-19, 2025. The company continues to supply products from the facility and will work with the FDA for compliance.
Read the summary - Medium impact
Sun Pharma's subsidiary to invest ₹3,000 crore in new facility
Sun Pharma's subsidiary, Sun Pharma Laboratories, will invest ₹3,000 crore to establish a new greenfield formulations manufacturing facility in Madhya Pradesh.
Read the summary - Medium impact
Sun Pharma launches Ilumya® in India for Plaque Psoriasis treatment
Sun Pharma launches Ilumya in India for treating moderate-to-severe plaque psoriasis. Clinical trials showed significant skin clearance and improvements. The drug is available in 35 countries.
Read the summary - Medium impact
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl)
FDA approved an updated label for Sun Pharma's UNLOXCYT™ for advanced CSCC treatment, based on positive long-term trial data. Commercial launch is expected in early 2026.
Read the summary - Medium impact
Scheme of Arrangement Effective Date
Sun Pharma announces that the Composite Scheme of Arrangement has been sanctioned by NCLT and is effective from November 22, 2025, following the filing of the order copy with the Registrar of Companies.
Read the summary - Medium impact
Sun Pharma & AstraZeneca partner for Hyperkalaemia treatment in India
Sun Pharma partners with AstraZeneca to enhance availability of Sodium Zirconium Cyclosilicate (SZC) for Hyperkalaemia treatment in India, with AstraZeneca marketing it as Lokelma® and Sun Pharma as Gimliand®.
Read the summary - Medium impact
Sun Pharma Presents Utreglutide Posters at ObesityWeek® & AHA Scientific Sessions
Sun Pharma presented data on Utreglutide at ObesityWeek® and AHA sessions, showing promising results in weight loss and metabolic improvements in obese individuals and post-menopausal women.
Read the summary - Medium impact
Philogen Provides Update on Fibromun Clinical Study Developments
Sun Pharma's partner, Philogen, updates on Fibromun clinical study. Phase III trial FIBROSARC did not meet its primary endpoint, but showed promising trends. Further studies are planned.
Read the summary - High impact
Sun Pharma Reports Strong Q2 FY26 Performance; Innovative Medicines Drive Growth, R&D Pipeline Advancing
Sun Pharma's Q2 FY26 consolidated sales grew 8.6% to ₹144,052 million; EBITDA up 14.9%. Innovative Medicines drove US growth. R&D pipeline advancing with H2 FY26 launches planned.
Read the summary - Low impact
Sun Pharma announces schedule of Analyst/Institutional Investor Meetings
Sun Pharma announced analyst/institutional investor meetings on 18-Nov-25 and 19-Nov-25 in Mumbai. The company will not disclose any Unpublished Price Sensitive Information (UPSI) at these meetings.
Read the summary - Low impact
Sun Pharma announces schedule of upcoming analyst/institutional investor meetings
Sun Pharmaceutical Industries Limited announced its schedule for upcoming analyst and institutional investor meetings on November 12 and 13, 2025, in Mumbai.
Read the summary - Low impact
Sun Pharma Publishes Unaudited Financial Results for Quarter and Half Year Ended September 30, 2025
Sun Pharma announced the newspaper publication of its unaudited financial results for the quarter and half year ended 30 September 2025, which were approved by the Board on 05 November 2025.
Read the summary - Low impact
Sun Pharma Announces Investor Call Audio Recording
Sun Pharma has released the audio recording of its investor call held on 05 November 2025. The recording is accessible on the company's website.
Read the summary - Medium impact
Sun Pharma Approves Q2 Results, MoA Amendment for Renewable Energy
Sun Pharma's board approves Q2 results and MoA amendment for renewable energy initiatives. The company will set up captive solar plants, and the NCLT approved the composite scheme of arrangement for amalgamation of subsidiaries on 07 October 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio